Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Macrophages and cancer.

P W Whitworth1, C C Pak, J Esgro

  • 1Department of Cell Biology, University of Texas M.D. Anderson Cancer Center, Houston.

Cancer Metastasis Reviews
|February 1, 1990
PubMed
Summary

Cancer metastases often resist treatment due to cellular diversity. Macrophage-activated therapy offers a promising approach to target and destroy these resistant cancer cells, potentially overcoming treatment resistance.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.

Oncogenesis·2013
Same author

MS-275 sensitizes osteosarcoma cells to Fas ligand-induced cell death by increasing the localization of Fas in membrane lipid rafts.

Cell death & disease·2012
Same author

Intratumor murine interleukin-12 gene therapy suppressed the growth of local and distant Ewing's sarcoma.

Cancer gene therapy·2006
Same author

Biologic response modifiers in pediatric cancer.

Hematology/oncology clinics of North America·2001
Same author

Growth suppression of established human osteosarcoma lung metastases in mice by aerosol gene therapy with PEI-p53 complexes.

Cancer gene therapy·2001
Same author

Enhanced etoposide sensitivity following adenovirus-mediated human topoisomerase IIalpha gene transfer is independent of topoisomerase IIbeta.

British journal of cancer·2001

Area of Science:

  • Oncology
  • Immunology
  • Nanomedicine

Background:

  • Metastatic cancer, characterized by uncontrolled growth and resistance to conventional therapies, is a leading cause of cancer-related mortality.
  • Metastases originate from specialized malignant cells within primary tumors and can exhibit clonal origins and increased mutation rates, leading to varied treatment sensitivities.
  • Neoplastic heterogeneity and acquired resistance present significant challenges for effective disseminated metastasis treatment.

Purpose of the Study:

  • To investigate the potential of activated macrophages as a therapeutic strategy against cancer metastases.
  • To explore the mechanism of macrophage-mediated tumor cell destruction and its independence from tumor-specific characteristics.
  • To evaluate the efficacy of in situ macrophage activation using liposome-encapsulated immunomodulators for cancer therapy.

Main Methods:

  • Activation of macrophages into tumoricidal cells using phospholipid vesicles (liposomes) containing immunomodulators.
  • In vitro and in vivo assessment of tumoricidal macrophage activity against neoplastic cells.
  • Administration of intravenously injected liposomes to achieve in situ macrophage activation and clearance by phagocytic cells.
  • Investigation of combination strategies involving chemotherapy or radiotherapy prior to macrophage-directed therapy.

Main Results:

  • Activated macrophages can specifically recognize and destroy neoplastic cells in vitro and in vivo, sparing nonneoplastic cells.
  • Macrophage-mediated tumor cell destruction is independent of tumor immunogenicity, metastatic potential, or drug sensitivity, and does not appear to induce tumor cell resistance.
  • In situ activation of macrophages via liposomal immunomodulators has demonstrated the eradication of cancer metastases in certain protocols.
  • Macrophage therapy is most effective when the initial tumor burden is minimal, highlighting the need for cytoreductive pre-treatments.

Conclusions:

  • Appropriately activated macrophages represent a viable therapeutic modality to overcome neoplastic heterogeneity and drug resistance in metastatic cancer.
  • Liposome-encapsulated immunomodulators enable in situ macrophage activation, offering a targeted approach for cancer metastasis treatment.
  • Macrophage-directed therapy shows promise for eliminating residual tumor cells that escape conventional treatments, with ongoing human trials providing valuable insights.

Related Experiment Videos